217 related articles for article (PubMed ID: 36300416)
1. Axillary Lymphadenopathy as an Initial Presentation of Systemic Amyloidosis: A Case Report and Literature Review.
Kumar S; Grell GR; Joseph G; Wang JC
J Investig Med High Impact Case Rep; 2022; 10():23247096221133191. PubMed ID: 36300416
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
3. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
Rybinski B; Kocoglu M
Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
[TBL] [Abstract][Full Text] [Related]
4. Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy.
Chitimus DM; Berling E; Garderet L; Venturelli N; Malfatti E; Authier FJ; Nicolas G; Laforêt P; Lefeuvre C
Eur J Neurol; 2023 Mar; 30(3):745-748. PubMed ID: 36403110
[TBL] [Abstract][Full Text] [Related]
5. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
6. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
[TBL] [Abstract][Full Text] [Related]
7. Macroglossia as the initial presentation of AL amyloidosis: review and updates in treatment.
Cherico AS; Rizvi A; Jayakrishnan T; Mewawalla P
BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35817492
[TBL] [Abstract][Full Text] [Related]
8. Primary Systemic Amyloidosis: A Case Report.
Oli SS; Jha A; Karki A; Sapkota S; Adhikari L
JNMA J Nepal Med Assoc; 2023 Oct; 61(266):822-824. PubMed ID: 38289775
[TBL] [Abstract][Full Text] [Related]
9. Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation.
Abdallah M; Sanchorawala V
Am J Med; 2022 Apr; 135 Suppl 1():S30-S37. PubMed ID: 35081382
[TBL] [Abstract][Full Text] [Related]
10. Progressive chorioretinal involvement in a patient with light-chain (AL) amyloidosis: a case report.
Augstburger E; Sahel JA; Audo I
BMC Ophthalmol; 2020 Feb; 20(1):59. PubMed ID: 32085748
[TBL] [Abstract][Full Text] [Related]
11. Isolated Lymph Node Amyloidosis: Response Assessment to Chemotherapy on Serial 18F-FDG PET/CT Scans.
Tripathy S; Bharadwaj M; Prakash S; Pramanik R; Mittal A; Shamim SA
Clin Nucl Med; 2020 Sep; 45(9):705-706. PubMed ID: 32604112
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
[TBL] [Abstract][Full Text] [Related]
13. Gastroduodenal Involvement in AL Amyloidosis: Case Report and Literature Review.
Ramachandran R; Grantham T; Isaac-Coss G; Etienne D; Reddy M
J Investig Med High Impact Case Rep; 2024; 12():23247096241237759. PubMed ID: 38462925
[TBL] [Abstract][Full Text] [Related]
14. [Treatment strategy for immunoglobulin light chain amyloidosis].
Fuchida SI
Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
[TBL] [Abstract][Full Text] [Related]
16. Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature.
Naymagon L; Abdul-Hay M
J Med Case Rep; 2019 May; 13(1):153. PubMed ID: 31113466
[TBL] [Abstract][Full Text] [Related]
17. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
Zhang Y; Duncanson L; Brayer J; Reu F; Hansen D; Alsina M; Nishihori T; Ochoa-Bayona J; Liu H; Shain K; Thompson Z; Baz R; Blue B
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e770-e776. PubMed ID: 35504808
[TBL] [Abstract][Full Text] [Related]
18. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Shen KN; Fu WJ; Wu Y; Dong YJ; Huang ZX; Wei YQ; Li CR; Sun CY; Chen Y; Miao HL; Zhang YL; Cao XX; Zhou DB; Li J
Circulation; 2022 Jan; 145(1):8-17. PubMed ID: 34503349
[TBL] [Abstract][Full Text] [Related]
19. IgG,kappa monoclonal gammopathy of unknown significance with AL amyloidosis simulating giant cell arteritis.
Pompilian VM; Tănăseanu Ş; Badea C; Zurac S; Socoliuc C; Badelita S; Botez E; Antohe M
Rom J Intern Med; 2017 Sep; 55(3):179-182. PubMed ID: 28467313
[TBL] [Abstract][Full Text] [Related]
20. Amyloid light-chain amyloidosis presenting as abdominal bloating: a case report.
Lee ASY; Lee DZQ; Vasanwala FF
J Med Case Rep; 2016 Mar; 10():68. PubMed ID: 27026530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
